In vivo toxicity of cationic micelles and liposomes

Knudsen, Kristina Bram; Northeved, Helle; Ek, Pramod Kumar; Permin, A.; Gjetting, Torben; Andresen, Thomas Lars; Larsen, Steen; Wegener, Karen Malene; Lykkesfeldt, Jens; Jantzen, Kim; Loft, Steffen; Möller, Peter; Roursgaard, Martin

doi:10.1016/j.nano.2014.08.004

Cited by 297 publications

(163 citation statements)

References 43 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Among others, Ollitrault et al developed a novel method applicable to primary chondrocytes or MSCs, by seeding the cells on collagen sponges prior to transfection of siRNA complexes targeting collagen type 1 and HTRA1, a secreted enzyme that is proposed to regulate the availability of IGFs, to induce chondrogenesis [36]. Unfortunately, lack of colloidal stability, moderate cytotoxicity, and potential immunoresponse restrict the therapeutic value of liposome-based carriers, as well as their in vivo application [40]. Nevertheless, research aimed at overcoming these issues is ongoing.…”

Section: Non-viral Methods Delivering Rnai For Chondrogenesismentioning

confidence: 99%

Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair

Lolli

Penolazzi

Narcisi

et al. 2017

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The field of cartilage repair has exponentially been growing over the past decade. Here, we discuss the possibility to achieve satisfactory regeneration of articular cartilage by means of human mesenchymal stem cells (hMSCs) depleted of anti-chondrogenic factors and implanted in the site of injury. Different types of molecules including transcription factors, transcriptional co-regulators, secreted proteins, and microRNAs have recently been identified as negative modulators of chondroprogenitor differentiation and chondrocyte function. We review the current knowledge about these molecules as potential targets for gene knockdown strategies using RNA interference (RNAi) tools that allow the specific suppression of gene function. The critical issues regarding the optimization of the gene silencing approach as well as the delivery strategies are discussed. We anticipate that further development of these techniques will lead to the generation of implantable hMSCs with enhanced potential to regenerate articular cartilage damaged by injury, disease, or aging.

show abstract

Section: Non-viral Methods Delivering Rnai For Chondrogenesismentioning

confidence: 99%

Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair

Lolli

Penolazzi

Narcisi

et al. 2017

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…Biocompatible metallic nanomaterials such as gold also have concerns of cellular and systemic toxicity due to surface ligands and/or the accompanying phagocytic immune responses (16,17). Moreover, plausible in vivo toxicity of biomaterial nanomaterials such as cationic micelles and liposomes has been addressed in the literature (18). Thus, various nanoparticles could have possible mechanisms of toxicity which are dependent on chemical composition, size, shape and surface molecules of nanoparticles (11).…”

Section: Radionanomedicine Facilitates Clinical Nanomedicine Trace Ammentioning

confidence: 99%

Translational radionanomedicine: a clinical perspective

Choi¹,

Lee²,

Hwang³

et al. 2016

European Journal of Nanomedicine

View full text Add to dashboard Cite

Many nanomaterials were developed for the anticipated in vivo theranostic use exploiting their unique characteristics as a multifunctional platform. Nevertheless, only a few nanomaterials are under investigation for human use, most of which have not entered clinical trials yet. Radionanomedicine, a convergent discipline of radiotracer technology and use of nanomaterials in vivo, can facilitate clinical nanomedicine because of its advantages of radionuclide imaging and internal radiation therapy. In this review, we focuse on how radionanomedicine would impact profoundly on clinical translation of nanomaterial theranostics. Up-to-date advances and future challenges are critically reviewed regarding the issues of how to radiolabel and engineer radionanomaterials, in vivo behavior tracing of radionanomaterials and then the desired clinical radiation dosimetry. Radiolabeled extracellular vesicles were further discussed as endogenous nanomaterials radiolabeled for possible clinical use.

show abstract

“…Cationic lipid-based vectors have several advantages including stability and favorable cellular internalization, while toxicity and protection of siRNA can be major challenges. 10,11 Various polymeric nanoparticles have also been explored for siRNA delivery, such as polyethylenimine (PEI), 12 chitosan, 13 and dendrimers.…”

Section: Introductionmentioning

confidence: 99%

VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer

Chen

Sun

Shao

et al. 2017

IJN

View full text Add to dashboard Cite

Angiogenesis plays an important role in tumor development and metastasis, and many cancer cells upregulate VEGF expression to promote angiogenesis. Silencing VEGF expression by RNA interference is expected to be a promising strategy to suppress the tumor growth. However, low transfection efficiency and instability are the main barriers for small interfering RNA (siRNA) delivery. In this study, we developed polycation liposome-encapsulated calcium phosphate nanoparticles (PLCP) for siRNA delivery in vivo. VEGF expression silencing effect in MCF-7 cells was investigated by real-time quantitative polymerase chain reaction and Western blot assay. VEGF siRNA mediated by PLCP can reduce 60%–80% VEGF expression in vitro, which was significantly higher than that mediated by Lipofectamine 2000. Furthermore, significant tumor growth and angiogenesis inhibition were observed in MCF-7 xenografts mice when treated with PLCP/VEGF siRNA or combined with doxorubicin. In conclusion, the combination of silencing VEGF expression and chemotherapeutics would be a potential treatment for cancer therapy.

show abstract

In vivo toxicity of cationic micelles and liposomes

Abstract: This study investigates the toxicity of cationic micelles and liposomes utilized as nanocarriers in gene and drug delivery, demonstrating its effects on the lungs, spleen and liver.

Cited by 297 publications

References 43 publications

Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair

Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair

Translational radionanomedicine: a clinical perspective

VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer

Contact Info

Product

Resources

About